Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 2.6 AUD 1.96%
Market Cap: 142.1m AUD

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is hidden AUD. Compared to the current market price of 2.6 AUD, Vita Life Sciences Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
64
Median 3Y
1.4
Median 5Y
1.4
Industry
2.6
vs History
1
vs Industry
35
Median 3Y
12.6
Median 5Y
12
Industry
21.7
vs History
39
vs Industry
25
Median 3Y
13.3
Median 5Y
13
Industry
16.7
vs History
41
vs Industry
22
Median 3Y
14.6
Median 5Y
14.6
Industry
23.1
vs History
25
vs Industry
37
Median 3Y
2.4
Median 5Y
2.5
Industry
2.2
vs History
20
vs Industry
71
Median 3Y
1.1
Median 5Y
1.1
Industry
2.9
vs History
23
vs Industry
74
Median 3Y
1.9
Median 5Y
1.9
Industry
5.5
vs History
6
vs Industry
42
Median 3Y
7.1
Median 5Y
7
Industry
13.2
vs History
6
vs Industry
44
Median 3Y
7.1
Median 5Y
7
Industry
16.8
vs History
39
vs Industry
32
Median 3Y
10.6
Median 5Y
10.6
Industry
15.9
vs History
39
vs Industry
28
Median 3Y
11.3
Median 5Y
11.1
Industry
19.2
vs History
26
vs Industry
29
Median 3Y
2.9
Median 5Y
2.9
Industry
1.9

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
145.4m AUD 1.7 15.6 9.2 9.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
258.9B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
211.4B GBP 4.9 30.3 109 159.6
CH
Novartis AG
SIX:NOVN
208.6B CHF 4.7 18.3 11.6 15
US
Merck & Co Inc
NYSE:MRK
260.5B USD 4.1 13.7 9.7 11.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.3B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 23.1
15.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.3
38%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 399.9
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.7
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBIT: 1 711.2
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.5
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3